Literature DB >> 17520195

Current understanding of precursors to pancreatic cancer.

Kyoichi Takaori1.   

Abstract

Precursors to pancreatic cancer have been investigated for a century. Previous studies have revealed three distinct precursors, i.e. mucinous cystic neoplasm (MCN), intraductal papillary mucinous neoplasm (IPMN), and pancreatic intraepithelial neoplasia (PanIN), harboring identical or similar genetic alterations as does invasive pancreatic carcinoma. The current understanding of precursors to pancreatic cancer can be illustrated by progressive pathways from noninvasive MCN, IPMN, and PanIN toward invasive carcinoma. MCNs consist of ovarian-type stroma and epithelial lining with varying grades of atypia, and are occasionally associated with invasive adenocarcinoma. The epithelium of noninvasive IPMNs shows a variety of different directions of differentiation, including gastric, intestinal, pancreatobiliary (PB), and oncocytic types. IPMNs can also harbor varying grades of architectural and cytologic atypia. IPMNs confined to branch ducts are mostly the gastric type, and IPMNs involving the main ducts are often intestinal type, while PB and oncocytic types are rare. Small (<1 cm) IPMNs of the gastric type are not always morphologically distinguishable from low-grade PanINs. Mucin expression profiles suggest intestinal-type IPMNs progress to mucinous noncystic (colloid) carcinoma, while PB-type IPMNs progress toward ductal adenocarcinoma. It is a well-described paradigm that PanIN lesions progress toward ductal adenocarcinoma through step-wise genetic alterations. The activation of Hedgehog and Notch signaling pathways in PanIN lesions as well as in pancreatic adenocarcinoma suggest that developmental pathways may be disregulated during carcinogenesis of the pancreas. Further study is needed to elucidate the pathways from precursors toward invasive carcinoma of the pancreas.

Entities:  

Mesh:

Year:  2007        PMID: 17520195     DOI: 10.1007/s00534-006-1165-6

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  17 in total

1.  Metachronous double cancer after curative resection for pancreatic adenocarcinoma: report of four cases.

Authors:  Yoshito Ikematsu; Hiroaki Tamura; Tadataka Hayashi; Yuji Tokunaga; Yuki Misawa; Hiroki Mori; Shinichi Hasegawa; Taketoshi Okawada; Takachika Ozawa; Shigeru Momiki; Yoshiro Nishiwaki
Journal:  Clin J Gastroenterol       Date:  2011-12-28

2.  MicroRNAs in pancreatic ductal adenocarcinoma.

Authors:  Jong Y Park; James Helm; Domenico Coppola; Donghwa Kim; Mokenge Malafa; Seung Joon Kim
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Ajay V Maker; Nora Katabi; Li-Xuan Qin; David S Klimstra; Mark Schattner; Murray F Brennan; William R Jarnagin; Peter J Allen
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

Review 4.  Current status of molecular markers for early detection of sporadic pancreatic cancer.

Authors:  Subhankar Chakraborty; Michael J Baine; Aaron R Sasson; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2010-10-01

5.  Feasibility and yield of screening in relatives from familial pancreatic cancer families.

Authors:  Emmy Ludwig; Sara H Olson; Sharon Bayuga; Jennifer Simon; Mark A Schattner; Hans Gerdes; Peter J Allen; William R Jarnagin; Robert C Kurtz
Journal:  Am J Gastroenterol       Date:  2011-04-05       Impact factor: 10.864

6.  Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.

Authors:  Ajay V Maker; Silvia Carrara; Nigel B Jamieson; Mario Pelaez-Luna; Anne Marie Lennon; Marco Dal Molin; Aldo Scarpa; Luca Frulloni; William R Brugge
Journal:  J Am Coll Surg       Date:  2014-11-06       Impact factor: 6.113

7.  Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Ajay V Maker; Nora Katabi; Mithat Gonen; Ronald P DeMatteo; Michael I D'Angelica; Yuman Fong; William R Jarnagin; Murray F Brennan; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2010-08-18       Impact factor: 5.344

8.  Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm.

Authors:  Wenqing Cao; Brain P Adley; Jie Liao; Xiaoqi Lin; Mark Talamonti; David J Bentrem; Sambasiva M Rao; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2009-12-01       Impact factor: 3.466

Review 9.  Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications.

Authors:  Praveen Guturu; Vijay Shah; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2009-06-10

10.  Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm.

Authors:  Koji Shindo; Shinichi Aishima; Kenoki Ohuchida; Minoru Fujino; Yusuke Mizuuchi; Masami Hattori; Takao Ohtsuka; Shoji Tokunaga; Kazuhiro Mizumoto; Masao Tanaka; Yoshinao Oda
Journal:  Virchows Arch       Date:  2014-07-03       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.